TIANJIN, China, Dec. 27 /Xinhua-PRNewswire/ -- Asymchem, one of China's leading CMO companies, announced today the Company's investment and expansion plans in China. Apart from new plants and R & D facility, the Company will also invest heavily in training and form strategic alliances in the near future.
I. Quality Facilities: New cGMP Pilot Plant and R&D Building became Operational in October, 2007
The new Asymchem Life Science (Tianjin) Co., Ltd site began operation with the opening of its new cGMP Pilot Plant in October 2007 and projected opening of a new R&D Building 1Q 2008. The initial investment for the site to date is 180 million RMB, with further construction on-going for completion in late 2008.
A total investment of 480 million RMB has been allotted for the 100,000 sqm site located in TEDA, Tianjin, one of the more prestigious high tech parks in China. Asymchem will build cGMP production facilities following ICH Q7A guidelines. Supporting facilities at this site will include an R&D center, an analytical research center and an EHS center that follow international standards. The goal is to achieve comprehensive facilities for development and production of cGMP intermediates and APIs at kilogram to mton scale. In the end, Asymchem will be in position to provide a variety of advanced technical services for pharmaceutical and biotech companies.
Phase I construction of Asymchem Life Science aims to build 12 separate cGMP production modules in a 50,000 sqm facility. Following ICH Q7A guidelines, these production modules with a total output of approximately 20mt of cGMP intermediate and APIs each year are designed according to international concepts and are equipped with advanced HVAQ systems. So far, many intermediates and API's of high value have been manufactured in this new facility.
In the meantime, a new R&D building with a construction area of 10,000 sqm will be built to allow >300 chemists working at the same time. This new R&D center, supported with sophisticated analytical instruments will be a necessary expansion of current R&D and Analytical Research capabilities. It is expected that the whole construction of Asymchem Life Science will complete in 2008. As a result, Asymchem's total production value will be of dynamic value to the pharmaceutical industry.
''Asymchem will be even better positioned to serve foreign pharmaceutical/biotech customers in a more professional and international way in the future. We will further increase our capacity in the production of pharmaceutical intermediates and drug substances and will build ourselves to a one-stop shop to international pharmas by means of combination of CMO and CRO,'' stated Dr. Hao Hong, Chairman & CEO of Asymchem. The operation of new cGMP production facility and R&D center will turn an important page for Asymchem's investment in China. Advanced development concept and unparalleled technologies will definitely drive the domestic industry to better serve international pharmaceutical and biotech companies.
II. Personnel Training: Asymchem's China Personnel Training Base Completes as Asymchem's Campus Recruitment grows nationally
On July 29, 2007, Asymchem's China Personnel Training Base is complete in Dunhua, Jilin province. With a modern design equipped with advanced multi- media systems, the base allows >60 people to meet together at the same time. Asymchem envisions this as a place for brainstorming, for delivery of company concepts and for employee enrichment. In July of 2007, the 3rd annual Asymchem management meeting was held in the base.
Dr. Hao Hong emphasized, ''Talent development always is the most vital part of Asymchem development and we always value this part highly.'' The completion of Asymchem's China Personnel Training Base enhances personnel training, delivers management concepts and, at the same time, enriches teamwork spirits.
Oct. 28, Asymchem started its 2008 Campus Recruitment Campaign along with the presentation on ''Devotion & Development'' nationally. The campaign includes >20 universities in >9 cities including Chongqing, Chengdu, Nanjing, Hangzhou, Wuhan, Harbin, Changchun, Lanzhou, Xi'an and Jinan. The goal is to add 350 new recruits of various levels, including 20 PhDs, 70 masters and 260 bachelors. Student recruitment and presentations are well received by potential new employees all over the country. As of Nov. 30, 2007, around 300 fresh students have decided to start their careers in Asymchem. Moreover, Asymchem is providing ''Asymchem TEDA Scholarship'' in universities like Sichuan University, Chongqing University and Lanzhou University to support students who are academically excellent but financially poor. More than 100 students have received funding from Asymchem since the beginning of the scholarship. Asymchem believes this campaign will attract more talented people to participate in the dynamic growth of the Asymchem organization.
III. More Investment: 1.68 billion RMB Investment in Dagang Established Asymchem Investment Model in China
Recently, Asymchem has come to an agreement with DEDA, Tianjin for a project with a total investment of 3 million RMB and a total area of 100,000 sqm. The project, which is the third one of Asymchem in the new Binhai area aims to produce cGMP intermediate and APIs on large scale following ICH Q7A guidelines. Recently, Asymchem established Asymchem Laboratories (Jilin) Co., Ltd in Dunhua, Jilin province, with initial capital of 240,000,000RMB.
Since 1998, Asymchem has strategically established 6 subsidiaries (3 in Tianjain, 1 in Fuxin, Liaoning, 1 in Hangzhou, Zhejiang and 1 in Dunhua, Jilin) in China with its own money. The total investment reaches 1.68 billion RMB. To date, Asymchem has established its own China development strategy -- headquartered in Tianjin with facilities in both Northeast and Southern China to involve all business including R&D, process optimization, manufacturing and product sales.
''Asymchem will surely further its investment in China in the future so as to much more quickly step into top CRO and CMO industries.'' Dr. Hao Hong spoke confidently.
Headquartered in Research Triangle Park in North Carolina, Asymchem is structured and balanced to develop and manufacture pharmaceutical intermediates and APIs in good quality to meet the demands of pharmaceutical and biotechnology customers. Asymchem has established a position of strength in the international pharmaceutical industry by strategic location of manufacturing facilities in China, relying on broad technical expertise and inherent respect for IP control. Since its beginning in 1998, Asymchem has gradually established 6 subsidiaries (3 in Tianjin, 1 in Fuxin, Liaoning, 1 in Hangzhou, Zhejiang and 1 in Dunhua, Jilin) in China with its own capital. The total investment currently reaches 1.68 billion RMB. Equipped with advanced technology and modern facilities, Asymchem endeavors to serve the pharmaceutical industry at all levels of production. For more information, please visit: http://www.asymchem.com or http://www.asymchem.com.cn
Copyright©2007 PR Newswire.
All rights reserved